The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 354, Issue 2, 1996, Pages 179-186

  Hauber, W ^a   Munkle M ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

adenosine; basal ganglia; catalepsy; dopamine; N methyl D aspartate (NMDA); rat

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; DIZOCILPINE; HALOPERIDOL; METIROSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RESERPINE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CENTRAL NERVOUS SYSTEM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT;

EID: 0029991617     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00178718     Document Type: Article

References (46)

1. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375
2. 2 dopamine agonist depends upon catecholaminergic neurons. Eur J Pharmacol 113:109-114
3. Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75-82
4. 2-dopamine receptor-mediated catalepsy. Brain Res 450:403-407
5. Casas M, Ferré S, Guix T, Jane F (1988) Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis. Biol Psychiatry 24:642-648
6. Collis MG, Hourani SMO (1993) Adenosine receptor subtypes. Trends Pharmacol Sci 14:360-366
7. Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology 26:1431-1440
8. Costall B, Naylor RJ, Olley JE (1972) Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology 11:645-663
9. Daly JW (1993) Mechanims of action of caffeine. In: Garrattini S (ed) Caffeine, coffe and health; Raven Press, New York pp 97-149
10. Deutch AY, Tam SY, Freeman AS, Bowers Jr MB, Roth RH (1987) Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur J Pharmacol 134:257
11. Ferré S, Guix T, Prat G, Jane F, Casas M (1990) Is experimental catalepsy properly measured? Pharmacol Biochem Behav 35:753-757
12. 2 receptors induces catalepsy. Neurosci Lett 130:162-164
13. 2 receptors in striatal membranes. Proc Natl Acad Sci USA 88:7238-7241
14. Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB (1992) Adenosine-dopamine interactions in the brain. Neuroscience 51:501-512
15. Ferré S, O'Connor WT, Fuxe K, Ungerstedt U (1993) The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 13:5402-5406
16. 2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Dev Res 28:374-380
17. Hauber W, Schmidt WJ (1993) Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats. J Neural Transm 94: 103-114
18. 2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate (NMDA) receptors. Neurosci Lett 196:205-208
19. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133
20. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990) NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555-556
21. 2 -selective agonist [3H]CGS 21680. Eur J Pharmacol 168:243-248
22. Jiang H, Jackson-Lewis V, Muthane U, Dollison A, Ferreira M, Espinosa A, Parsons B, Przedborski S (1993) Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 613:347-351
23. 2A receptor antagonist with anticataleptic activity. Eur J Pharmacol 256:263-268
24. Kretschmer BD, Zadow B, Volz TL, Schmidt WJ (1992) The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J Neural Transm 87:23-35
25. Liljequist S, Ossowska K, Grabowska-Andén M, Andén N-E (1991) Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 195:55-61
26. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15:298-307
27. Löscher W, Annies R, Hönack D (1993) Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 242:263-274
28. Londos C, Cooper DMF, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77:2551-2557
29. Maj J, Skuza G, Rogóż Z (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J Neural Transm 6:53-62
30. Mally J, Stone TW (1994) The effect of theophylline on parkinsonian symptoms. J Pharm Pharmacol 46:515-517
31. 2A receptor modulation of electrically evoked endogenous GABA release from slices or rat globus pallidus. J Neurochem 60:2334-2337
32. 2 receptor-mediated inhibition of GABA release in slices of rat globus pallidus. Soc Neurosci Abstr 20:638.11
33. Ossowska K, Wedzony K, Wolfarth S (1984) The role of the GABA mechanisms of the globus pallidus in mediating catalepsy, stereotypy and locomotor activity. Pharmacol Biochem Behav 21:825-831
34. Ossowska K (1994) The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm 8:39-71
35. 2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res 631:161-166
36. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990) Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem 54:1157-1162
37. Sanberg PR, Giordano M, Bunsey MD, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748-759
38. Scheel-Krüger J, Magelund G, Olianas MC (1981) Role of GABA in the striatal output systems: globus pallidus, nucleus entopeduncularis, substantia nigra and nucleus subthalamicus. In: Di Chiara G, Gessa GL (eds) GABA and the basal ganglia. Raven, New York, pp 165-186
39. 2A receptor expression in striatal neurons: implications for basal ganglia pathophysiology. Drug Dev Res 28: 381-385
40. Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623
41. Schmidt WJ, Bubser M, Hauber W (1990) Excitatory amino acids and Parkinson's disease. Trends Neurosci 13:46
42. Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm 38:65-89
43. Snyder SH (1985) Adenosine as a neuromodulator. Ann Rev Neurosci 8: 103-124
44. Spanagel R, Eilbacher B, Wilke R (1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat a pharmacokinetic microdialysis study. Eur J Pharmacol 262:21-26
45. Svensson A, Pileblad H, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm 85:117-129
46. Van Calker D, Muller D, Hamprecht B (1979) Adenosine regulates via two different types of receptors the accumulation of cAMP in cultured brain cells. J Neurochem 33:999-1005